Discover
AVDL
Avadel Pharmaceuticals PLC
21.64
2 x 15.60
2 x 27.73
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
21.65 +0.01 (0.05%)
| Ytd | 0.42% | |
| 1y | 140.71% |
21.63
day range
21.76
52 week range
| Open | 21.65 | Prev Close | 21.64 | Low | 21.63 | High | 21.76 | Mkt Cap | N/A |
| Vol | 35.02M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | 27.74 |
| Beta | 1.63 | Short Ratio | 1.60 | Inst. Own | 86.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 20.71 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-03-02 | 2025-12 | 0.08 | N/A | N/A | N/A |
| 2025-11-04 | 2025-09 | 0.04 | N/A | N/A | N/A |
| 2025-08-07 | 2025-06 | 0.02 | N/A | N/A | N/A |
| 2025-05-07 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-03 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-11-12 | 2024-09 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-11-20 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2025-11-07 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2025-10-28 | UBS | Downgrade | Buy | Neutral |
| 2025-10-23 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-10-23 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2025-10-22 | Jefferies | Downgrade | Buy | Hold |
Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-07-28 | AMIN NASEEM M.D. | Director | 22.00K | Stock Award(Grant) |
| 2025-03-04 | DIVIS GREGORY J. JR. | Chief Executive Officer | 221.10K | Stock Award(Grant) |
| 2025-07-28 | ENDE ERIC J | Director | 219.90K | Stock Award(Grant) |
| 2025-07-28 | GLASS GEOFFREY MICHAEL | Director | 166.98K | Stock Award(Grant) |
| 2026-02-03 | MCCAMISH MARK ANTHONY | Director | 0.00 | Stock Gift |
| 2025-03-04 | MCHUGH THOMAS S | Chief Financial Officer | 100.40K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Janus Henderson Group PLC | 7.43M | 160.78M | 7.57% |
| 2025-12-30 | Blackrock Inc. | 7.04M | 152.37M | 7.17% |
| 2025-12-30 | Vanguard Group Inc | 5.86M | 126.91M | 5.98% |
| 2025-09-29 | Gendell, Jeffrey L. | 5.31M | 115.01M | 5.41% |
| 2025-09-29 | Polar Capital Holdings PLC | 4.00M | 86.55M | 4.07% |
| 2025-09-29 | Vivo Capital, LLC | 2.68M | 58.08M | 2.73% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.87M | 62.20M | 2.93% |
| 2025-12-30 | iShares Trust-iShares Russell 2000 ETF | 2.26M | 48.80M | 2.30% |
| 2025-09-29 | JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.50M | 32.53M | 1.53% |
| 2025-09-29 | JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.44M | 31.19M | 1.47% |
| 2025-09-29 | Datum One Series Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND | 1.15M | 24.87M | 1.17% |
| 2025-09-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.03M | 22.27M | 1.05% |